Shares of Xeris Pharmaceuticals XERS rose 3% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share were up 50.78% over the past year to ($0.63), which beat the estimate of ($0.73).
Revenue of $2,027,000 up by 533.44% year over year, which beat the estimate of $1,860,000.
Guidance
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
How To Listen To The Conference Call
Date: Aug 10, 2020
Time: 08:30 AM
ET Webcast URL: https://www.directeventreg.com/der/toRegistration.action
Price Action
Company's 52-week high was at $12.50
52-week low: $1.42
Price action over last quarter: Up 13.93%
Company Profile
Xeris Pharmaceuticals Inc is a specialty pharmaceutical company leveraging its novel non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize ready-to-use injectable and infusible drug formulations. Its pipeline products are Diazepam, Pramlintide-Insulin, Self-Administered Glucagon, and others.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
